Moderna share lower: earlier deliveries for Germany – two vaccination doses only help to a limited extent against Omikron
Earlier deliveries of the preparation from Moderna are in sight for the corona vaccinations in Germany.
Specifically, 10 million vaccine doses can be brought forward to December, as EU circles said on Thursday. A further 25 million cans can therefore be brought forward into the first quarter of 2022. From the total of 35 million doses, up to 70 million doses could be drawn for booster vaccinations, as half a dose is used for this at Moderna.
The federal government had already announced on Wednesday that it would buy an additional 80 million doses of the preparation from BioNTech through EU contracts. The budget committee of the Bundestag had approved around 2.2 billion euros for this and for 12 million other cans that are to be procured directly.
Two Moderna vaccination doses only protect against Omikron to a limited extent
Two vaccinations with the product of the US manufacturer Moderna protect against Omikron less well than against certain earlier variants. This is shown by a laboratory study by US researchers – including employees of the National Institutes of Health (NIH) and Moderna – which was published as a preprint, i.e. not in a peer-reviewed journal.
According to this, four weeks after the second dose vaccinated people had significantly fewer antibodies against the Omikron variant than against certain earlier variants in their blood. In order to examine the effect of a vaccine against a certain variant of Sars-CoV-2, researchers usually do so-called neutralization tests. It is checked how many antibodies a vaccinated person has in the blood that can reach the virus variant and thus switch it off. The actual protection of vaccinated persons cannot be determined with this, however, clinical studies with thousands of test persons or evaluations of the ongoing infection process are required.
The number of antibodies directed against Omikron increased significantly about two weeks after a booster vaccination with Moderna. According to the study, a booster dose could significantly reduce the risk of the disease. However, the team concludes that it is only a matter of laboratory tests. In addition, there was a lack of data on how long the reaction of the neutralizing antibodies lasted after the booster vaccination.
The vaccine manufacturers Biontech (BioNTech (ADRs)) and Pfizer announced last week that three doses of their product were necessary for adequate protection against the Omikron variant. According to initial laboratory data, two doses did not provide sufficient protection against infection with this recently discovered variant. However, the companies assumed that protection against serious illness would continue to exist.
The Moderna share temporarily lost 0.44 percent to 282.76 US dollars in US trading on the NASDAQ.
BERLIN / BRUSSELS (dpa-AFX)